Equities analysts predict that Eli Lilly and Co (NYSE:LLY) will post sales of $5.47 billion for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Eli Lilly and’s earnings, with the lowest sales estimate coming in at $5.42 billion and the highest estimate coming in at $5.53 billion. Eli Lilly and posted sales of $5.23 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.6%. The company is scheduled to report its next quarterly earnings results on Tuesday, April 24th.
According to Zacks, analysts expect that Eli Lilly and will report full-year sales of $5.47 billion for the current financial year, with estimates ranging from $23.05 billion to $23.67 billion. For the next financial year, analysts expect that the business will post sales of $23.84 billion per share, with estimates ranging from $23.30 billion to $24.17 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Eli Lilly and.
Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. Eli Lilly and’s revenue was up 7.0% on a year-over-year basis.
Shares of Eli Lilly and (NYSE:LLY) opened at $79.04 on Tuesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01. The stock has a market capitalization of $87,220.55, a P/E ratio of -395.18, a price-to-earnings-growth ratio of 1.48 and a beta of 0.28. Eli Lilly and has a 52 week low of $73.69 and a 52 week high of $89.09.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 212,261 shares of company stock worth $18,627,485. Company insiders own 0.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares during the last quarter. BlackRock Inc. raised its position in Eli Lilly and by 1.2% during the 4th quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after purchasing an additional 776,893 shares during the last quarter. Franklin Resources Inc. raised its position in Eli Lilly and by 2.7% during the 4th quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock worth $2,408,787,000 after purchasing an additional 754,681 shares during the last quarter. Janus Henderson Group PLC raised its position in Eli Lilly and by 16.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after purchasing an additional 1,503,918 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Eli Lilly and by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock worth $830,522,000 after purchasing an additional 406,812 shares during the last quarter. Institutional investors own 77.58% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.